Jan. 19, 2018
On January 19, 2018, Japan-based Eisai Co. announced that it has entered into a licensing agreement granting exclusive rights concerning the research, development, manufacture and marketing of Eisai's in-house discovered potential anticancer agent to China-based Adlai Nortye Biopharma in all regions outside of Japan and part of Asia.
E7046, an investigational prostaglandin E2 (PGE2) type EP4 receptor antagonist, is an orally administered, selective EP4 receptor antagonist discovered by Eisai's U.S. Andover research facility.
Currently, E7046 is being investigated as a monotherapy in a Phase I clinical study as well as a Phase Ib clinical study in combination with radiotherapy/ chemoradiotherapy.
Under this agreement, Eisai will receive an upfront and milestone payments from Adlai Nortye in accordance with the progress of development, as well as certain royalties according to sales revenue after launch.